Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md.,…
CORRECTION: RadNets DeepHealth Subsidiary Expands FDA Clearance for SmartMammo Solution
November 29, 2024 09:43 ET | Source: RadNet, Inc. SmartMammo™’s AI algorithm…
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
November 27, 2024 16:10 ET | Source: Applied Therapeutics NEW YORK, Nov.…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…